

# CURRICULUM VITAE

<b>Name</b>	<b>Dr. Karl-Hermann Schlingensiepen</b>
<b>Date and Place of Birth</b>	<b>22.03.1960, Bonn</b>
<b>Nationality</b>	<b>German</b>
<b>Present Position</b>	<b>Chief Executive Officer</b>
<b>Professional Experience</b>	
Since Nov. 1998	Chief Executive Officer, Antisense Pharma GmbH, Regensburg, Germany
1996 – 1998	Head of Business Development, Intellectual Property and Marketing, Biagnostik GmbH, Göttingen, Germany
1995 – 1996	Head of R&D and Product Strategy, Biagnostik GmbH, Göttingen, Germany
1990 – 1995	Head of Laboratory, AG Molekulare Tumorbilogie & Antisense Technologie at the Max-Planck-Institut f. Biophysikalische Chemie, Göttingen, Germany
1987 - 1990	Postdoc at the MPI f. Biophysikalische Chemie
<b>Professional Training</b>	
1987	Ph.D., Max-Planck-Institut, Göttingen, Germany
<b>Awards</b>	
2004	- German Founders Award; 1st Prize in the category of „entrepreneur visionary“
2004	- Bavarian Innovation Award, 1st Prize
1991	- Upjohn International Award <i>American Association for Cancer Research</i> (AACR)
1985/86	- Special Fellowship, Studienstiftung des dt. Volkes
1983-86	- Scholar, Studienstiftung des dt. Volkes
1983/84	- Scholar, Deutscher Akademischer Austausch Dienst (DAAD)
<b>Educational Background</b>	
	<b>Studies of Medicine (MD)</b>
1986	The Johns Hopkins University, U.S.A.
1985	Harvard University, U.S.A.
1984 – 1985	Göttingen University, Germany
1983 – 1984	Cambridge University, U.K.
1980 - 1983	Göttingen University, Germany
<b>Language Skills</b>	German, English

## Consent:

I agree that my curriculum vitae may be presented to auditors and governmental representatives for the purpose of audits and inspections.

19. Jan 2011      K-H Schlingensiepen  
Date / Signature

## Bibliography K.-H. Schlingensiepen

67. Schlingensiepen K.-H., Jaschinski F., Lang S.A., Moser C., Geissler E.K., Schlitt H.J., Hafner M., Kielmanowicz M. and Schneider A. Preclinical Investigation of TGF- $\beta$ 2 Gene Silencing with Trabedersen (AP 12009) for the Treatment of Pancreatic Cancer. (*submitted*)
66. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., Balasubramaniam A., Nair S., Oliushine V., Parfenov V., Poverennova I., Zaaroor M., Jachimczak P., Ludwig S., Schmaus S., Heinrichs H., Schlingensiepen K.-H., and the trabedersen glioma study group. Targeted Therapy for High-Grade Glioma with the TGF- $\beta$ 2 Inhibitor Trabedersen: Results of a Randomized and Controlled Phase IIb Study. (*submitted*)
65. Schlingensiepen K.-H., Schmaus S., Jaschinski F., Schneider A., Jachimczak P., Seitz C., Blass B. and Heinrichs H. The TGF- $\beta$ 2 Inhibitor Trabedersen (AP 12009) for the Treatment of Pancreatic Cancer and Other Malignant Tumors, in *Chemotherapy and targeted therapy in pancreatic cancer*. Ed. Hilbig A. (*in press*).
64. Schlingensiepen K.-H., Jachimczak P., Blass B., Schmaus S., Seitz C. and Heinrichs H. Antisense-Nukleinsäuren in der Therapie maligner Tumoren, in *Onkologie: Grundlagen - Diagnostik - Therapie - Entwicklungen*. Eds. Zeller W.J. and zur Hausen H., Ecomed: Landsberg/Lech. p. IV-20 (2010).
63. Schlingensiepen, K.-H., Fischer-Blass B., Schmaus S., Ludwig S. The TGF-beta2 Inhibitor AP 12009 in Clinical Development against Malignant Tumors. *Recent Results in Cancer Research - Accomplishments in the Treatment of Pancreatic Cancer*. Eds. Oettle H., Riess H. p. 137-50 (2008).
62. Schlingensiepen, K.-H., Jachimczak P., Fischer-Blass B., Fischer D., Specht H., Schmaus S., Schlingensiepen R. Targeted Downregulation of TGF-beta2 with AP 12009 in Tumor Therapy. *Transforming Growth Factor-beta in Cancer Therapy*; Beverly Teicher's Methods in Molecular Biology series on Cancer Drug Discovery and Development. Ed. Jakowlew S. The Humana Press Inc.: Totowa. p. 635-651 (2008).
61. Hau P., Jachimczak P., Schlingensiepen R., Schulmeyer F., Jauch T., Steinbrecher A., Brawanski A., Proescholdt M., Schlaier J., Buchroithner J., Pichler J., Wurm G., Mehdorn M., Strege R., Schuierer G., Villarrubia V., Fellner F., Jansen O., Straube T., Nohria V., Goldbrunner M., Kunst M., Schmaus S., Stauder G., Bogdahn. U and K.-H. Schlingensiepen. Downregulation of TGF- $\beta$ 2 as novel cancer therapy: From preclinical to clinical proof of concept in high-grade glioma. *Oligonucleotides*, **17(2)**: 201-212 (2007).
60. Schlingensiepen K.-H., Schlingensiepen R., Steinbrecher A., Hau P., Bogdahn U., Fischer-Blass B. and P. Jachimczak. Targeted Tumor Therapy with the TGF- $\beta$ 2 Antisense Compound AP 12009. *Cytokine Growth Factor Rev.* **17(1-2)**: 129-139 (2006).
59. Schlingensiepen K.-H., Fischer-Blass B., Jachimczak P. and R. Schlingensiepen. The role of transforming growth factor-beta in carcinogenesis. *Nature Rev Cancer* **5(12)**: published online only: <http://www.nature.com/nrc/index.html>.
58. Schlingensiepen R., Fischer-Blass B., Fischer D., Hafner M., Specht H., Hau P., Bogdahn U., Jachimczak P. and K.-H. Schlingensiepen. Immuntherapie gegen Maligne

Tumore mit Antisense AP 12009: Technologie, Target, Therapie. *Journal Onkologie* **7**: 28-33 (2005).

57. Schlingensiepen R., Goldbrunner M., Szyrach M.N., Stauder G., Jachimczak P., Bogdahn U., Schulmeyer F., Hau P. and K.-H. Schlingensiepen. Intracerebral and Intrathecal Infusion of the TGF-beta2-Specific Antisense Phosphorothioate Oligonucleotide AP 12009 in Rabbits and Primates: Toxicology and Safety. *Oligonucleotides* **15(2)**: 94-104 (2005).

56. Jachimczak P., Apfel R., Bosserhoff A.K., Fabel K., Hau P., Tschertner I., Wise P., Schlingensiepen K.-H., Schuler-Thurner B. and U. Bogdahn. *Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques*. *Int. J. Cancer* **113(1)**: 88-92 (2005).

55. Schlingensiepen K.-H., Schlingensiepen R.: An antisense oligonucleotide to inhibit "Melanoma Inhibitory Activity", MIA, WO 2005/014812, February 17th, 2005.

54. Bosserhoff A., Büttner R., Schlingensiepen K.-H., Auerbach G., Jachimczak P., Szyrach M. A method for inhibiting "Melanoma Inhibitory Activity" MIA, WO 03/06445 A1, August 7th, 2003.

53. Schlingensiepen K.-H., Schlingensiepen R., Apfel R., Brysch W., Jachimczak P., Bogdahn U. A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "MIA", WO 01/681 122 A2, September 20th, 2001.

52. Schlingensiepen K.-H., Schlingensiepen R. Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene, WO 01/68 146 A2, September 20th, 2001.

51. Maus U.A., Herold S., Schlingensiepen K.-H., Schlingensiepen R., Dormayr T., Rosseau S., Maus R., Seeger W. and J. Lohmeyer. Antisense oligomers for selective suppression of MCP-1 synthesis in human pulmonary endothelial cells. *Antisense Nucleic Acid Drug Dev.* **10(3)**: 185-93 (2000).

50. Schlingensiepen K.-H., Schlingensiepen R., Brysch W. A method for stimulating the immune system, WO 99/63 975, December 16th, 1999.

49. Schlingensiepen K.-H., Brysch W. An antisense oligonucleotide preparation method, WO 98/33904, August 6th, 1998.

48. Schlingensiepen K.-H. and R. Schlingensiepen. Oncology: Developing Antisense Therapeutics for Tumor Treatment. In: Schlingensiepen, R., Brysch, W. & Schlingensiepen, K.-H. (eds.) *Antisense: From Technology to Therapy: Lab Manual and Textbook*. Blackwell Science, Berlin, Vienna 1997, (1997), pp. 272-301.

47. Schlingensiepen K.-H. and M. Heilig. Neurobiology: Gene Function Analysis and Therapeutic Prospects in Neurobiology. In: Schlingensiepen, R., Brysch, W. & Schlingensiepen, K.-H. (eds.) *Antisense: From Technology to Therapy: Lab Manual and Textbook*. Blackwell Science, Berlin, Vienna 1997, (1997), pp. 186-223.

46. Schlingensiepen R. and K.-H. Schlingensiepen. Introduction: Antisense Oligodeoxynucleotides - Highly Specific Tools for Basic Research and Pharmacotherapy. In: Schlingensiepen, R., Brysch, W. & Schlingensiepen, K.-H. (eds.) *Antisense: From*

*Technology to Therapy: Lab Manual and Textbook*. Blackwell Science, Berlin, Vienna 1997, (1997), pp. 3-28.

45. Rifai A., Brysch W., Fadden K., Clark J. and K.-H. Schlingensiepen. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. *Am. J. Pathol.*, **149**: 717-725 (1996).

44. Zurmöhle U., Herms J., Schlingensiepen R., Brysch W. and K.-H. Schlingensiepen. Changes in the expression of synapsin I and II mRNA during postnatal rat brain development. *Exp. Brain Res.*, **108**: 441-449 (1996).

43. Jachimczak, P., Hessdoerfer, B., Fabel-Schulte, K., Brysch, W., Schlingensiepen, K.-H., Bauer, A., Blesch, A. and U. Bogdahn. Transforming growth factor-beta-mediated autocrine growth regulation as detected with phosphorothioate antisense oligonucleotides. *Int. J. Cancer*, **65**: 1-6 (1996).

42. Brysch W., Rifai A., Tischmeyer W. and K.-H. Schlingensiepen. Antisense-Mediated Inhibition of Protein Synthesis: Rational Drug Design, Pharmacokinetics, Intracerebral Application and Organ Uptake of Phosphorothioate Oligodeoxynucleotides *in-vivo*. In Agrawal, S. (ed.) *Antisense Oligonucleotide Therapy: Current Status*. Humana Press, New Jersey, (1996), pp. 159-182.

41. Heilig M. and K.-H. Schlingensiepen. Antisense Oligodeoxynucleotides as Novel Neuropharmacological Tools for Selective Expression Blockade in the Brain. In: Latchman, D.S. (ed.) *Genetic Manipulation of the Nervous System*. Academic Press, London, (1996), pp. 249-263.

40. Schlingensiepen G.-F., Schlingensiepen R., Schlingensiepen K.-H. and W. Brysch. A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neuroplasms, WO 95/02 051, January 19th, 1995.

39. Brysch W., Schlingensiepen K.-H., Schlingensiepen R. and G.-F. Schlingensiepen. Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role, WO 95/17 507, June 29th, 1995.

38. Schlingensiepen K.-H. and W. Brysch. Antisense Nukleinsäuren in der Therapie maligner Tumoren. In: H. zur Hausen, W.J. Zeller (eds.) *Onkologie* Ecomed, Landsberg. 1995, pp. IV-20, 1-10.

37. Jachimczak, P., Fabelschulte, K., Hessdorfer, B., Brysch, W., Schlingensiepen, K.H., Blesch, A. and U. Bogdahn. Transforming growth factor-beta-mediated regulation of human peripheral blood mononuclear cell proliferation as detected with phosphorothioate antisense oligodeoxynucleotides. *Cell. Immunol.*, **165**: 125-133 (1995).

36. Schmidt, R., Brysch W., Rother, S. and K.-H. Schlingensiepen. Inhibition of memory consolidation after active avoidance conditioning by antisense intervention with endymin gene expression. *J. Neurochem.*, **65**: 1465-1471 (1995).

35. Rother S., Schmidt, R., Brysch W. and K.-H. Schlingensiepen. Learning Induced Expression of Meningeal Ependymin mRNA and Demonstration of Ependymin in Neurons and Glial Cells. *J. Neurochem.*, **65**: 1456-1464 (1995).
34. Bertram J., Palfner K., Killian M., Brysch W., Schlingensiepen K.-H., Hiddemann W. and M. Kneba. Reversal of multiple drug resistance *in vitro* by phosphorothioate oligonucleotides and ribozymes. *Anti-Cancer Drugs*, **6**: 124-134 (1995).
33. Paulus W., Baur I., Huettner C. Schmaußer B., Roggendorf W., Schlingensiepen K.-H. and W. Brysch. Effects of transforming growth factor-beta1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. *J. Neuropath. & Exp. Neurol.*, **54**: 236-244 (1995).
32. Wollnik F., Brysch W., Gillardon F., Bravo R., Zimmermann M., Schlingensiepen K.-H. and T. Herdegen. Block of c-Fos and JunB expression by antisense oligonucleotides inhibits light induced phase shifts of the mammalian clock. *Europ. J. Neurosci.* **7**: 388-393 (1995).
31. Schlingensiepen K.-H., Kunst M., Gerdes W. and W. Brysch. Complementary expression patterns of *c-jun* and *junB* in rat brain and analysis of their function with antisense oligonucleotides. In: Zieglgänsberger W., Tölle T. (eds.) *Immediate early genes in the Central Nervous System*. Springer, Berlin, Heidelberg, New York. pp. 132-145 (1995).
30. Schlingensiepen G.-F., Brysch W., Schlingensiepen K.-H., Schlingensiepen R., Bogdahn U.. Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor- $\beta$  (TGF- $\beta$ ), WO 94/25 588, November 10th, 1994.
29. Brysch W., Schlingensiepen R. and K.-H. Schlingensiepen. Antisense-mediated modulation of gene expression. Considerations for *in-vitro* and *in-vivo* applications. In Kriegstein, J. & Oberpichler-Schwenk, H. (eds.) *Pharmacology of Cerebral Ischemia* pp. 479-487 (1994).
28. Schlingensiepen K.-H., Wollnik F., Kunst, M., Schlingensiepen, R., Herdegen, T and W. Brysch. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death and in plastic adaptations *in-vivo*. *Cell. Mol. Neurobiol.*, **14**: 487-505 (1994).
27. Brysch W., Magal E., Louis J., Kunst, M., Klinger I., Schlingensiepen R. and K.-H. Schlingensiepen. Inhibition of p185/*c-erbB-2* proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation. *Cancer Gene Therapy*, **1**: 99-105 (1994).
26. Brysch W. and K.-H. Schlingensiepen. Design and application of antisense oligonucleotides in cell-culture, *in-vivo* and as therapeutic agents. *Cell. Mol. Neurobiol.*, **14**: 557-568 (1994).
25. Tischmeyer W., Grimm, R. Schicknick, H. Brysch W. and K.-H. Schlingensiepen. Sequence-specific impairment of learning by *c-jun* antisense oligonucleotides. *Neuroreport*, **5**: 1501-1504 (1994).

24. Herms J., Zurmöhle U., Brysch W. and K.-H. Schlingensiepen. Ca<sup>2+</sup>/Calmodulin Protein Kinase and Protein Kinase C expression during development of rat hippocampus. *Dev. Neurosci.*, **1**: 410-416 (1994).
23. Schlingensiepen, R., Terlau, H., Brysch, W. and K.-H. Schlingensiepen. Differential expression of *c-jun*, *junB* and *junD* in rat hippocampal slices. *Neuroreport*, **6**: 101-104 (1994).
22. Bertram J., Kilian M., Brysch W., Schlingensiepen K.-H. and M. Kneba. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. *Biochem. Biophys. Res. Commun.*, **200**:661-667 (1994).
21. Zurmöhle U., Herms J., Schlingensiepen, R. Schlingensiepen K.-H. and W. Brysch. Changes of synapsin I mRNA expression during rat brain development. *Exp. Brain Res.*, **99**:17-24 (1994).
20. Herms J., Zurmöhle U., Schlingensiepen, R. Brysch W. and K.-H. Schlingensiepen. Developmental expression of the transcription factor zif/EGR-1 in rat brain: an in situ hybridization study. *Neurosci. Lett.*, **165**: 171-174 (1994).
19. Jachimczak P., Bogdahn U., Schneider J., Behl C., Meixensberger J., Apfel R., Dörries R., Schlingensiepen K.-H., and W. Brysch. TGF- $\beta$ 2-specific Phosphorothioate-Antisense oligodeoxynucleotides may reverse cellular immunosuppression in malignant glioma. *J. Neurosurg.*, **78**: 944-951 (1993).
18. Behl C., Bogdahn U., Winkler J., Apfel R., Brysch W., and K.-H. Schlingensiepen. Autoinduction of platelet derived growth factor (PDGF)-A-chain mRNA and growth inhibition by PDGF-A specific phosphorothioate-oligodeoxynucleotides in human malignant glioma. *Biochem. Biophys. Res. Comm.*, **193**: 744-751 (1993).
17. Behl C., Winkler J., Bogdahn U., Meixensberger J., Schlingensiepen K.-H., and W. Brysch. Autocrine Growth Regulation in Neuroectodermal Tumors as Detected with Oligodeoxynucleotide Antisense Molecules. *Neurosurg.*, **33**: 679-684 (1993).
16. Schlingensiepen K.-H., Schlingensiepen R., Kunst, M., Klinger, I., Gerdes, W. Seifert, W. and W. Brysch. Opposite functions of Jun-B and c-Jun in growth regulation and neuronal differentiation. *Dev. Genetics*, **14**: 305-312 (1993).
15. Herms J., Zurmöhle U., Schlingensiepen K.-H. and W. Brysch. Transient expression of PKC-g mRNA in cerebellar granule cells during rat brain development. *Neuroreport*, **4**: 899-902 (1993).
14. Herms, J., Zurmöhle, U., Brysch, W. and K.-H. Schlingensiepen. Ca<sup>2+</sup>/calmodulin protein kinase and protein kinase C expression during development of rat hippocampus. *Dev Neurosci.*, **15**(6): 410-6 (1993).
13. Schlingensiepen K.-H. and W. Brysch. Phosphorothioate Oligomers: Inhibitors of oncogene expression in Tumor cells and tools for gene function analysis. In: R. P. Erickson and J. G. Izant (eds.) *Gene Regulation: Biology of antisense RNA and DNA*, Raven Press, New York pp. 317-328 (1992).

12. Flott-Rahmel B., Gerdes W., Pechan P., Brysch W., Schlingensiepen K.-H. and W. Seifert. bFGF induces its own gene expression in astrocytic and hippocampal cell cultures. *NeuroReport*, **3**: 1077-1080 (1992).
11. Schmidt R., Rother S., Schlingensiepen K.-H. and W. Brysch. Neuronal plasticity depending on a glycoprotein synthesized in goldfish leptomeninges. *Progr. Brain Res.*, **91**: 7-12 (1992).
10. Gerdes W., Brysch W., Schlingensiepen K.-H. and W. Seifert. Antisense bFGF oligodeoxynucleotides inhibit DNA synthesis of rat astrocytes. *NeuroReport*, **3**: 43-46 (1992).
9. Brysch W., Creutzfeldt O., Lüne K., Schlingensiepen, R. and K.-H. Schlingensiepen. Regional and temporal expression of sodium channel mRNAs in the rat brain during development *Exp. Brain Res.*, **86**: 562-567 (1991).
8. Schlingensiepen K.-H., Lüne K. and W. Brysch. High basal expression of the *zif/268* immediate early gene in cortical layers IV and VI, in CA1 and in the corpus striatum - an in situ hybridization study. *Neurosci. Lett.*, **122**: 67-70 (1991).
7. Brysch W., Brysch I., Creutzfeldt O., Schlingensiepen R. and K.-H. Schlingensiepen. The topology of the thalamo-cortical projections in the marmoset monkey (*Callithrix jacchus*) *Exp. Brain Res.*, **81**: 1-17 (1990).
6. Kneba M., Eick S., Willigeroth S., Bolz I., Herbst H., Pott C., Bergholz M., Brysch W., Schlingensiepen K.-H. and G. Krieger. Polymerase Chain Reaction Analysis of t(14;18) Junctional Regions in B-Cell Lymphomas. *Leukemia and Lymphoma*, **3**: 109-117 (1990).
5. Brysch W., Hagendorff G. and K.-H. Schlingensiepen. RNA probes, transcribed from synthetic DNA, for *in situ* hybridization. *Nucl. Acids Res.*, **16**: 2333 (1988).
4. Roberts S., Murgatroyd P., Crisp J., Nohria V., Schlingensiepen K.-H. and A. Lucas. Long-term variation in oxygen consumption in preterm infants. *Biol. Neonate*, **52**: 1-8 (1987).
3. Roberts S., Coward W., Schlingensiepen K.-H., Nohria V. and A. Lucas A. Comparison of the double labelled water (2H218O) method with indirect calorimetry and a nutrient balance study for simultaneous determination of energy expenditure, water intake and metabolizable energy in preterm infants. *Am. J. Clin. Nutr.*, **44**: 315-322 (1986).
2. Schlingensiepen K.-H., Campbell F., Legge G. and T. Walker. The importance of eye movements in the analysis of simple patterns. *Vision Res.*, **26**: 1111-1117 (1986).
1. Brysch I., Brysch W., Creutzfeldt O., Hayes N. and K.-H. Schlingensiepen. The second, intralaminar thalamo-cortical projection system. *Anat. Embryol.*, **169**: 111-118 (1984).

**Textbook Editor:**

Antisense: From Technology to Therapy: Lab Manual and Textbook. Schlingensiepen, R., Brysch, W. & Schlingensiepen, K.-H. (eds.) Blackwell Science, Berlin, Vienna (1997).